Glioblastoma (GBM) is the most malignant brain tumor of adults and is characterized by extensive cell dissemination within the brain parenchyma and enhanced angiogenesis. Effective preclinical modeling of these key features suffers from several shortcomings. Aim of this study was to determine whether modulating the expression of extracellular matrix (ECM) modifiers in proneural (PN) and mesenchymal (MES) cancer stem cells (CSCs) and in conventional glioma cell lines (GCLs) might improve tumor invasion and vascularization. To this end, we selected secreted, acidic and rich in cysteine-like 1 (SPARCL1) as a potential mediator of ECM remodeling in GBM. SPARCL1 transcript and protein expression was assessed in PN and MES CSCs as well as GCLs, in their xenografts and in patient-derived specimens by qPCR, WB and IHC. SPARCL1 expression was then enforced in both CSCs and GCLs by lentiviral-based transduction. The effect of SPARCL1 gain-of-function on microvascular proliferation, microglia activation and advanced imaging features was tested in intracranial xenografts by IHC and MRI and validated by chorioallantoic membrane (CAM) assays. SPARCL1 expression significantly enhanced the infiltrative and neoangiogenic features of PN and MES CSC/GCL-induced tumors, with the concomitant activation of inflammatory responses associated with the tumor microenvironment, thus resulting in experimental GBMs that reproduced both the parenchymal infiltration and the increased microvascular density, typical of GBM.
Introduction
Glioblastoma (GBM) is the deadliest brain tumor in adults and is characterized by extensive tumor cell dissemination within the brain that jeopardizes complete tumor removal, leading to refractoriness to treatment and invariable tumor recurrence (Olar and Aldape, 2014) . With respect to other gliomas, GBM is characterized by extremely rapid infiltrative growth and enhanced angiogenesis. Different molecular subtypes of GBM have been identified, with the genetic classification of GBM based on the IDH1 status being recently included into the histologic criteria-based diagnosis by the 2016 WHO classification of brain tumors (Louis et al., 2016) . Very interestingly, a transcriptomics-based subtyping of GBM into proneural (PN), classical (CL) and mesenchymal (MES) subgroups has also been proposed (Phillips et al., 2006) (Verhaak et al., 2010) (Wang et al., 2017) . The PN signature correlates with a slightly less aggressive disease and increased response to anti-angiogenic treatment in patients with IDH-wild-type GBM, whereas the MES subgroup is associated with enhanced angiogenesis, radio-resistance and poorer prognosis (Prados et al., 2015) .
The availability of preclinical in vivo models reproducing both the histopathological and molecular features of the distinct transcriptional subgroups of GBM may provide a significant benefit to the field of neuro-oncology, as they can be exploited as valuable tools to dissect pathogenetic mechanisms and test patient-tailored treatments. Specifically, xenograft models, as those derived from the implantation of subgroup-specific cancer stem cells (CSCs) into immune-deficient mice, may be representative of the molecular complexity of GBM, while being easily attainable (Abounader, 2018) .
CSCs can be isolated from GBM surgical specimens by the NeuroSphere Assay (NSA) and they can establish long-term renewing cell lines growing in suspension as neurospheres (Singh et al., 2003) (Galli et al., 2004) (Lee et al., 2006) . Notably, the majority of CSC lines grown under the NSA conditions show a tendency to maintain or acquire molecular and pathological features typical of the PN transcriptional subgroup of GBMs, independent of the subgroup affiliation of the tumor of origin (Bhat et al., 2013) (Narayanan et al., 2018) .
Upon intracranial transplantation, PN CSCs, cultured as neurospheres, are prone to give rise to highly infiltrative xenografts, which express canonical PN markers such as ASCL1, Olig2 and PDGFR (Narayanan et al., 2018) and show a very limited extent of neoangiogenesis, as tumor cells preferentially coopt the preexisting brain vasculature, thus resembling low-grade rather than highgrade gliomas (Galli et al., 2004) (Narayanan et al., 2018) (Mazzoleni et al., 2010) (Eskilsson et al., To be noted, other modalities of CSC culturing, as those exploiting adherent conditions (Pollard et al., 2009 ), seem to better preserve the original subgroup identity of the GBM cell lines obtained (Xie et al., 2015) . However, even under these in vitro conditions, adherent PN CSCs generate tumors that spread diffusely throughout the brain parenchyma, while MES xenografts grew expansively in nodular patterns, clearly demarcated from the normal parenchyma (Xie et al., 2015) .
As such, either type of subgroup-specific preclinical model of GBM only partially reproduces the histopathological traits of the tumor, likely due to the downregulation of the expression of critical factors as a consequence of in vitro culturing.
To promote the neoangiogenic potential of PN CSC-derived xenografts and the infiltrative ability of MES CSC-derived tumors, thus making available more authentic and comprehensive rodent xenograft models of GBM than those currently available, we looked for mediators involved in extracellular matrix (ECM) remodeling, a process known to facilitate both angiogenesis and tumor infiltration. To this end, we focused our attention on a member of the secreted, acidic and rich in cysteine (SPARC) family of matricellular proteins, i.e. SPARC-like 1 protein (SPARCL1), which we previously reported as being more highly expressed in more angiogenic EGFR neg CSCs than in less angiogenic EGFR pos CSCs (Mazzoleni et al., 2010) . SPARCL1 is present in the ECM as a dynamically expressed non-structural protein, whose function is dependent on the type of tissue and on the presence of specific molecules, such as the aggrecanase ADAM Metallopeptidase With Thrombospondin Type 1 Motif 4 (ADAMTS4) that cleaves SPARCL1 into a peptide, termed SPARC-like fragment (SLF), which inhibits cell adhesion and stimulate cell migration (Weaver et al., 2011) . Most remarkably, SPARCL1 is a critical component of a chemoattractant complex regulating the spreading of glioma cells within the brain and their interaction with neural stem cells (Qin et al., 2017) .
Here we report that enforcing SPARCL1 expression significantly enhances the infiltrative and neoangiogenic features of PN and MES CSC/GCLs-induced tumors, which are accompanied by increased inflammation, thus making the histopathological features of preclinical PN and MES GBMs more faithful of the ones observed in clinical samples than previous models.
J o u r n a l P r e -p r o o f
Journal Pre-proof
Results

SPARCL1 expression correlates with EGFR expression in human GBM PN CSCs.
Human EGFR neg and EGFR pos PN CSCs, classified based on EGFR protein expression, have been formerly shown to give rise to xenografts showing different level of angiogenesis, with EGFR neg PN CSCs being more angiogenic than EGFR pos (Mazzoleni et al., 2010) (Supplementary Fig. S1 ). To identify gene(s) potentially promoting angiogenesis, we took advantage of previously-generated microarray-based transcriptional data of EGFR neg and EGFR pos CSCs and compared, by supervised clustering analysis, the gene expression profile of EGFR neg CSC lines L0104, L0512 and L0125 with that of EGFR pos CSC lines L0605, L0306 and L0627 (Mazzoleni et al., 2010) . Notably, 264 genes, ranked based on a log2 fold change >1 in expression with a p<0.05 significance, were differentially expressed between the two conditions (Supplementary List S1). In line with previous findings (Mazzoleni et al., 2010) , one of the genes upregulated in EGFR neg CSCs vs. EGFR pos CSCs was SPARCL1. SPARCL1 mRNA and protein were confirmed being significantly more highly expressed in EGFR neg CSCs than in EGFR pos CSC lines ( Fig. 1A-B ). Accordingly, SPARCL1 expression was observed in a higher number of tumor cells in xenografts generated by the intracranial implantation of EGFR neg CSCs than in those induced by EGFR pos CSCs (Fig. 1C) .
To assess whether SPARCL1 expression held a clinical significance, we queried transcriptional information from the TCGA data set (Tumor Glioblastoma-TCGA-540-MAS5.0) of human GBM specimens, by using the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl).
SPARCL1 mRNA was expressed at very high levels in all the 4 transcriptional subgroups of GBM, thus implying that it might play a critical role in GBM (Fig. 1D ). In agreement with R2-based transcriptional analysis, GBM specimens, molecularly classified by immunohistochemistry (IHC) for specific subgroup-restricted markers, showed similar SPARCL1 protein expression in the two main molecular subgroups, i.e. proneural and mesenchymal (n=6 and n=10 patients for PN and MES, respectively) ( Fig. 1E ).
SPARCL1 overexpression promotes extensive neoangiogenesis in PN CSC-derived intracranial xenografts.
To understand whether SPARCL1 might promote the acquisition of malignant features in GBM CSCderived xenografts, we started by overexpressing SPARCL1 in both EGFR pos (i.e. L0605 and L0306) and EGFR neg (i.e. L0512 and L0125) PN CSCs by lentiviral-mediated transduction. Both SPARCL1 mRNA and protein were significantly more highly expressed in SPARCL1-transduced CSCs than in CSCs transduced with a control vector coding for GFP (mock) ( Supplementary Fig. S2A-B ).
In line with its main role in mediating interactions with ECM in vivo, SPARCL1 overexpression in CSCs did not result in any significant difference in CSC morphology, long-term self-renewal, J o u r n a l P r e -p r o o f Journal Pre-proof proliferation rate, differentiation potential and invasive ability in vitro (data not shown). Likewise, we did not detect any significant alteration in signaling pathways associated with CSC physiology, e.g. AKT, ERK and mTOR ( Supplementary Fig. S2C ). However, the expression of ADAMTS4, the aggrecanase required for SPARCL1 cleavage into the active fragment, was slightly but significantly increased at the mRNA and protein level in SPARCL1-transduced CSCs in vitro ( Supplementary   Fig. S2D-E) .
Next, we set out to test whether SPARCL1 overexpression might elicit any effect in vivo. To this end, we transplanted orthotopically EGFR pos L0605 and EGFR neg L0512 CSCs transduced with either GFP or SPARCL1 into nude mice (n=4 animals/condition/CSC line for two independent experiments). In line with in vitro results, enhanced SPARCL1 expression in vivo, which was comparable ( Supplementary Fig. S3 ) to that seen in human GBM specimens (Fig. 1E) , did not significantly affect either tumor growth or the overall survival of tumor-bearing mice (data not shown). Nonetheless, the extent of angiogenesis as assessed by IHC for CD31 was strongly increased in SPARCL1-transduced CSC-derived xenografts as compared to tumors derived from mock CSCs, in terms of both vessel number and area (vessel number and area per 20x field) ( Fig. 2A-B) The increase was particularly evident in tumors derived from EGFR pos CSCs, whose basal level of SPARCL1 and angiogenesis is low.
To understand whether the enlarged and tortuous vessels detected in SPARCL1-derived tumors were newly formed, immature vessels, we analyzed the degree of association of pericytes to endothelial cells in GFP-and SPARCL1-derived tumors. A tight lining of PDGFRβ pos pericytes was detected in most vessels retrieved in control xenografts, indicating that they were differentiated, mature and stable ( Fig. 2A, insets) . Conversely, reduced and discontinuous pericyte coverage was found in the majority of vessels in SPARCL1-transduced CSC-derived xenografts, implying that these vessels were immature and neoangiogenic ( Fig. 2A, insets) .
SPARCL1-overexpressing PN CSC-derived xenografts are endowed with angio-architectural patterns resembling those observed in patients.
Since both vessel number and area were unevenly distributed within SPARCL1-transduced CSCderived tumors, we analyzed the same parameters in three distinct anatomical compartments, classified as tumor core (TC), tumor periphery (TP), and tumor perilesional area (PA) (Fig. 3A) . TP was defined as the peripheral area of the lesion, extending inside the tumor for 1 mm from the tumor border, whereas the PA was defined as the area of brain parenchyma surrounding the lesion, extending outside the tumor for 0.5 mm from the tumor border (Fig. 3A) . The TC was identified as the remaining portion of the tumor (Fig. 3A) .
Angiogenesis was significantly increased in all the three areas in SPARCL1-transduced CSCderived tumors when compared to controls, and, in particular, higher vessel number and larger vessel J o u r n a l P r e -p r o o f Journal Pre-proof area were retrieved in the TP than in TC (Fig. 3B -C and Supplementary Fig. S4A ). This pattern was reminiscent of GBM in patients, in which blood supply is typically supported by a peripheral ringshaped active vasculature surrounding a central necrotic tumor core (Jain et al., 2007) .
Another typical angiogenic feature of GBMs is the capability to recruit vessels from the surrounding brain parenchyma to sustain tumor growth. To assess whether this feature was present in tumors after overexpression of SPARCL1, we compared the angiogenic profile of the perilesional area in GFP-and SPARCL1-transduced CSC-derived xenografts. SPARCL1-overexpressing tumors displayed a significantly enhanced vessel recruitment in the PA as compared to controls ( Fig. 3B-C) .
In agreement with these results, publicly available RNA sequencing data for anatomic structures isolated by laser microdissection in a collection of 122 samples from 10 human GBMs (Ivy Glioblastoma Atlas Project, Ivy Gap; http://glioblastoma.alleninstitute.org) indicated that SPARCL1 expression was significantly higher in the infiltrating part and in in the leading edge of the tumor than in the rest of the tumor (Fig. 3D ).
To understand whether SPARCL1 expression was directly regulating neoangiogenesis in CSCderived xenografts, we performed different angiogenic-specific assays in vitro and ex-vivo. Firstly, we assessed the expression of known angiogenic factors in CSCs overexpressing GFP or SPARCL1 by qPCR. In line with previous in vitro analyses, no consistent difference was detected in the expression of HIF1, VEGF and POSTN, when assessed in CSC cultures after SPARCL1 overexpression ( Supplementary Fig. S4B ).
Next, we evaluated the sprouting and proliferation of human umbilical vein endothelial cells (HUVECs) after stimulation with either mitogen-supplemented or mitogen-free conditioned media (CM) from CSCs overexpressing GFP or SPARCL1. No significant differences in terms of spheroid formation and proliferation were detected with any CM collected from either GFP-or SPARCL1transduced CSCs (data not shown).
As such, we hypothesized that a more complex microenvironment than that provided by twodimension endothelial cell cultures could be required to dissect the effect of SPARCL1 on angiogenesis. To this end, we exploited the ex-vivo three-dimension chick embryo chorioallantoic membrane (CAM) assay. Several CAMs were exposed to mitogen-supplemented CM and only the CM from SPARCL1-overexpressing EGFR neg CSC was able to induce a significant angiogenic response ( Fig. 3E) . Since the continuous production of SPARCL1, whose lability in vitro has been previously documented (Weaver et al., 2011) , together with the direct contact of CSCs with the microenvironment might be necessary for the full pro-angiogenic effect to take place, we assessed the direct proangiogenic effect of GFP-and SPARCL1-overexpressing CSCs by placing them on top of the CAM. Under these conditions, a statistically relevant promotion in vessel outgrowth was observed with all SPARCL1-transduced CSC lines as compared to controls (Fig. 3E ).
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SPARCL1 role in angiogenesis may also be mediated indirectly by the interaction with the hostderived microenvironment. To assess the contribution of microglia/macrophages in GFP-and SPARCL1-transduced CSC-derived xenografts, IHC was performed by antibodies directed against Iba1, a known molecular marker of both resting and activated microglia as well as of macrophages, and the number of microglia/macrophages quantified in the three distinct tumor compartments ( Fig.   4A) .
As compared to controls, SPARCL1-transduced CSC-derived tumors showed increased numbers of Iba1 pos cells ( Fig. 4B and Supplementary Fig. S5A ). In line with the compartmentalized vessel analysis (Fig. 3) , xenografts generated from SPARCL1-transduced CSCs showed a significant increase in the number of microglial cells located in the TP as compared to the TC (Fig. 4B-C) .
When functionally activated, microglial cells assume a round, ameboid-like shape. A significant increase in ameboid Iba1 pos cells was retrieved in xenografts generated by SPARCL1-transduced
CSCs as compared to controls, thus suggesting that there might be an increase in microglia activation upon SPARCL1 overexpression (Fig. 4D) .
We next took advantage of the previously described bioinformatics tool R2 to explore the relationship between SPARCL1 expression and the nature of the immune infiltrate (Zhao et al., 2018) . In line with in vivo results, Pearson correlation analysis on the TCGA GBM data set indicated a positive correlation between the expression of SPARCL1 in patients' GBMs and that of total tumorassociated macrophages/microglia markers such as Iba1 (AIF1) (r-value=0.301, p-value=8.4e-13) and CD11b (ITGAM) (r-value=0.267, p-value=2.8e-10) ( Fig. 4E) . A significant positive correlation was found for the M2 macrophage markers CD163 (r-value=0.134, p-value=1.7e-03) and a positive trend for iNOS (NOS2) (r-value=0.055, p-value=0.20) (Fig. 4E) , while no correlation was found with the M1-associated markers HLA-DR and CD11c (ITGAX) (data not shown). Similar findings were retrieved when the smaller-sized Ivy Gap dataset was used, with significant correlation observed for Iba1 (Supplementary Fig. S6 ). Therefore, a global increase in tumor-associated macrophages might be involved in mediating the SPARCL1-dependent angiogenic phenotype, thus again reproducing a pattern similar to that observed in highly malignant GBMs.
When correlation analysis was performed by taking advantage of expression data of the selected anatomic areas reported in the Ivy Gap dataset, a positive correlation was found between SPARCL1 and CD163 (r-value=0.628) and a positive trend with the remaining genes in the cellular portion of the tumor (Supplementary Fig. S6 ). On the contrary, anticorrelation was detected between SPARCL1 and Iba1 (r-value=-0.506), CD163 (r-value=-0.64) and CD11c (r-value=-0.413) in the infiltrative region of the tumor (Supplementary Fig. S6) . Correlation in the remaining tumor areas was not significant (not shown). Intracranial xenografts generated by PN CSCs do not enhance at MRI after contrast agent administration (Mazzoleni et al., 2010) . Indeed, PN CSCs co-opt the pre-existing vasculature and do not alter the blood-brain barrier (BBB), as they give rise to highly infiltrative tumors, which are characterized by hyperintensity in T2-weighted images and hypointensity in T1-weighted images (Di Tomaso et al., 2010) .
To assess if SPARCL1-dependent pro-angiogenic effect could result in MRI-detectable changes in microvascular density and/or BBB permeability, anatomic T1-weighted/T2-weighted, dynamiccontrast enhancement (DCE) and diffusion tensor imaging (DTI) analyses were performed on Rowett Nude female rats transplanted with GFP-and SPARCL1-overexpressing L0605 CSCs by a 7-Tesla small animal-dedicated MRI equipment.
In agreement with findings in mice, vessel number, vessel area and Iba pos cells were increased in SPARCL1-overexpressing CSC-derived tumors in rats ( Fig. 5A and Supplementary Fig. S5B ).
An increase in post-gadolinium enhancement by T1-weighted MRI (Fig. 5B) and in tumor vascularity through quantification of plasma volume (v p ) by perfusion-weighted DCE analysis (Fig.   5C ) was observed in SPARCL1-overexpressing tumors ( Supplementary Table 1 ), suggesting the occurrence of both BBB disruption and increased vessel density.
In addition, the tumor volume segmented on T2-weighted images in SPARCL1-overexpressing tumors was smaller than the tumor volume segmented on diffusion tensor-derived pure isotropy (p) maps ( Fig. 5D and Supplementary Table 1) , implying that SPARCL1 expression might promote extensive infiltration of single tumor cells within the brain parenchyma.
SPARCL1 expression in glioma cell lines (GCLs) and mesenchymal CSCs enhances neoangiogenesis and induce invasion.
Up to this point, we demonstrated that increasing SPARCL1 expression in PN CSCs strongly promotes their neoangiogenic potential and parenchymal invasion, thus significantly contributing to the improvement of high-grade glioma features in PN CSC-derived preclinical models. Next, we set out to test whether SPARCL1 overexpression might elicit the same effect in GBM cells endowed with mesenchymal features. To this end, we first took advantage of traditional glioma cell lines (GCLs), such as U87 and U373, and then validated the findings in a NSA-grown MES CSC line, i.e. L1312, which is known to retain a mesenchymal phenotype (Narayanan et al., 2018) . Of note, GCLs and MES CSCs show a poorly invasive growth pattern in vivo, thus not reproducing this critical pathognomonic feature of GBM. On the contrary, they both give rise to tumors with enhanced neoangiogenesis (Galli et al., 2004) (Narayanan et al., 2018) . Although patients' MES GBMs express significant levels of SPARCL1 transcript and protein (Fig.   1) , GCLs and MES CSCs did not, when compared to PN CSCs ( Supplementary Fig. S7A-B) , implying that in vitro culturing might have selected for cell clones that did not express SPARCL1 and suggesting that the regulation of neoangiogenesis in MES cells may be primarily SPARCL1independent. Nonetheless, when SPARCL1 was overexpressed in these cell lines ( Supplementary   Fig. S7C-D) , we observed a significant further increase in vessel density and area as compared to mock cells, as well as the presence of immature vessels with scarce pericyte coverage, as previously detected in SPARCL1-transduced PN CSC-derived xenografts (Fig. 6A-B) . Likewise, enhanced infiltration by tumor-associated macrophages/microglial cells was also retrieved, in particular at the TP, in xenografts from SPARCL1-overexpressing GCLs (Fig. 6C-D) .
SPARCL1 overexpression in non-infiltrative GCLs and MES CSCs also significantly promoted in vivo invasive ability, as shown by modifications occurring at the tumor-parenchyma boundary, with the well-delimited tumor border typical of GCLs and MES CSCs being interrupted by clusters of tumor cells departing from the main tumor mass (Fig. 6E ).
SPARCL1-induced neoangiogenesis is not primarily mediated by microglia.
To understand whether SPARCL1 acted directly or indirectly to promote angiogenesis by interacting with microglia, we treated mice transplanted with GFP-or SPARCL1-overexpressing U87 GCLs with two different CSFR1 inhibitors, namely GW2580 and PLX3397. The GW2580 inhibitor is a highly specific CSFR1 inhibitor able to induce 30% depletion of microglia cells and to reduce their proliferation (Olmos-Alonso et al., 2016). On the contrary, PLX3397 inhibitor is slightly less specific, as it inhibits also Flt3 and c-Kit receptors on vessels, but is highly effective in microglia depletion (60-90% efficiency of microglia ablation) (Peranzoni et al., 2018) .
Mice transplanted with GFP-transduced U87 cells were fed with a control chow (GFP CTR; n=4), while those transplanted with SPARCL1-transduced U87 cells were treated with a) a control chow (SPARCL1 CTR; n=4), b) a GW2580-containing chow (SPARCL1 GW2580; n=4) and c) a PLX3397-containing chow (SPARCL1 PLX3397; n=4).
No treatment-related changes in tumor volume were detected (data not shown). In line with previous reports, the frequency of Iba1 pos cells was significantly reduced after treatment with either of the inhibitors (Fig. 7A-B) . However, the number of vessels and their area were decreased to a much lower extent, suggesting that microglia may only partially mediate the SPARCL1-induced increase in angiogenesis ( Fig. 7A-B ).
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Only a small set of preclinically-tested drugs have been shown to successfully enter clinical trialing, likely due to limitations in the preclinical pipeline of cancer models (Floc'h et al., 2018) .
Conventional cell line-derived xenografts showed scarce resemblance with the original tumors, in particular in terms of tumor heterogeneity. Likewise, patient-derived xenografts demonstrated limited value in anticipating clinical trial response at the population level (Floc'h et al., 2018) .
The translational relevance of preclinical in vivo models concerns also GBM modeling. GBM is a highly heterogenous cancer, which comprises cells with distinct molecular profiles. Indeed, a recent study reported that cells belonging to 4 main different cell lineage related-states may be identified by single cell-RNA seq in a collection of GBM patients (Neftel et al., 2019) . These 4 states again recapitulated the 3 main molecular subgroups, i.e. proneural, classical and mesenchymal. Most notably, although each GBM sample did comprise cells belonging to all 4 different fates, a predominant cell population could be retrieved, indicating that most GBM samples could be safely affiliated to a specific subgroup. Due to the complexity and heterogeneity of the disease, no preclinical model is currently available that mimics all the relevant histopathological and molecular features of the tumor (Abounader, 2018) .
Others and we reported that PN GBM CSCs give rise to intracranial tumors that tend to recapitulate features of low-grade gliomas, as they are characterized by high tissue infiltration and very limited neoangiogenesis (Bhat et al., 2013) (Narayanan et al., 2018) . Since enhanced angiogenesis is a major GBM hallmark, preclinical models that lack this ability may suffer from severe limitations in predicting therapy responsiveness. Conversely, mesenchymal GBM xenografts, as those promoted by transplantation of conventional GCLs and MES CSCs, while being endowed with extensive microvascular proliferation, do not show any sign of parenchymal infiltration (Narayanan et al., 2018) . As such, although PN and MES CSCs reproduce many histological features of either subgroup, effective preclinical modeling reproducing all GBM characteristics has not been achieved to date.
Here we report that by modulating the expression of a single ECM interactor, i.e. SPARCL1, we promoted the acquisition of neoangiogenic traits in PN CSC-derived xenografts and the enhancement of infiltration in GCL/MES CSC-derived tumors.
SPARCL1 is an antiadhesive protein that exert tumorigenic or anti-tumorigenic activity depending on the tumor type. In colorectal cancer, the expression of SPARCL1 is considered a reliable marker for early diagnosis as well as a prognostic factor in patients (Zhang et al., 2011) .
Conversely, in pancreatic cancer SPARCL1 shows anti-invasive activity and is lowly expressed in metastasis (Esposito et al., 2007) .
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Journal Pre-proof Concerning gliomas, in line with our findings, SPARCL1 protein expression was reported to increase concomitant with tumor grade (Turtoi et al., 2012) . Moreover, SPARCL1 is a required mediator of the complex responsible for the invasion-promoting effect of subventricular zone progenitors during infiltration of glioma cells in the brain, thus reinforcing its role as pro-invasive factor (Qin et al., 2017) .
SPARC, also referred to as osteonectin or BM-40, is the prototypical member of the large family of SPARC matricellular proteins (Jones and Bouvier, 2014) . Interestingly, the increase in tumor infiltration that we observed following SPARCL1 overexpression in GCLs/MES CSCs is in line with previous findings demonstrating that enhancing SPARC expression in U87 cells result in tumor cells invading the brain as tumor satellites (Schultz et al., 2002) (Thomas et al., 2010) . However, as opposed to the reported SPARC antiproliferative activity (Schultz et al., 2002) (Thomas et al., 2010) , we did not observe any significant inhibitory effect of SPARCL1 on tumor growth, thus suggesting that SPARC and SPARCL1 act differently in regulating glioma pathogenesis. Accordingly, whereas SPARC suppresses glioma vascularization (Yunker et al., 2008) , here we demonstrate that SPARCL1 enhanced this feature in both CSC-and GCL-derived xenografts. As such, SPARCL1 seems to serve as a better molecular candidate than SPARC to promote the acquisition of GBM infiltrative and angiogenic properties, while not affecting tumor growth.
Under hypoxia, pseudopalisading regions in GBM activate ECM proteins (e.g. matrix metalloproteinases, protease-activated receptors, etc.) that induce GBM cells to migrate away from vessels (Brat et al., 2004) . As the tumor cells retract, they secrete proangiogenic factors that stimulate neoangiogenesis and outward expansion of tumor towards the newly formed vessels (Rong et al., 2006) . As such, also the increase in vessel recruitment at the perilesional tumor border, where tumor cells are actively infiltrating as single cells , might be directly mediated by SPARCL1. Advanced MRI analysis seems to corroborate these observations, as the higher tumor volume on diffusion tensor-derived isotropy maps than in T2-weighted images may reflect a more invasive tumor phenotype of SPARCL1-overexpressing tumors than controls (Price et al., 2017) .
GBM are characterized by a high degree of infiltration by immune cells that actively participate to ECM remodeling. Our findings suggest that SPARCL1 expression in CSC-derived xenografts promotes the increase of innate immunity cells, such as microglia and pro-tumorigenic M2 macrophages, that is another qualifying feature of highly malignant gliomas. In fact, data obtained after depletion of microglia reinforce the notion that SPARCL1 is the main and direct mediator of tumor neovascularization and that the role of microglia is mostly ancillary.
In summary, the above-described GBM mouse models are endowed with relevant characteristics that should facilitate their exploitation by researchers studying GBM. To date, the lack of any significant clinical impact of GBM molecular subtyping has diminished the importance of studies focused on investigating GBM molecular subtypes. The availability of CSC-derived mouse models J o u r n a l P r e -p r o o f Journal Pre-proof that recapitulate simultaneously the molecular features of GBMs (e.g. proneural and mesenchymal CSCs) and their major histopathological characteristics (tissue invasion, angiogenesis and tumorimmune host microenvironment cross-talk) will provide a valuable and unprecedented experimental tool to be exploited for a reliable preclinical testing that takes into account the molecular subgroup affiliation of GBM.
Material and methods
In vitro culture of GBM CSCs and GCLs
PN and MES GBM CSCs, established at the Neural Stem Cell Biology Unit, San Raffaele Scientific Institute, Milan, Italy and validated in (Narayanan et al., 2018) and (Mazzoleni et al., 2010) , were cultured under the conditions of the NeuroSphere Assay (NSA) (Galli et al., 2004) . GCL lines were grown in DMEM containing 10% fetal bovine serum (FBS) (Galli et al., 2004) .
Microarray-Based Gene Expression Profiling
Total RNA was isolated from CSCs using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA).
Biotinylated cRNA probes were synthesized using the GeneChip Whole Transcript Sense Target Labeling Assay Kit (Affymetrix) and then hybridized for 17hr at 45°C on GeneChip® Human Gene 1.0 ST Array (Affymetrix). Details of bioinformatics analysis are provided as Supplementary Methods.
Quantitative real-time PCR
One μg of total RNA was reverse-transcribed by using first strand synthesis kit Superscript III RNaseH -Reverse Transcriptase (Invitrogen, Carlsbad, CA) and OligodT primers. Quantitative realtime PCR was performed by the IQ SybrGreen technology (Biorad, Hercules, CA, USA) following manufacturer's instructions. ß-actin was used as housekeeping gene. Human-specific primers for SPARCL1 were purchased from Sigma (KiCqStart™ Primers). Data analysis was performed by the ΔΔC t method.
Bright-field immunohistochemistry
The retrospective study on human samples was conducted in compliance with the Declaration of Helsinki and with policies approved by the Ethics Board of Spedali Civili di Brescia, University of Brescia. For retrospective and exclusively observational study on archival material obtained for diagnostic purpose, patient consent was not needed.
Two µm sections were cut from paraffin blocks containing subgroup-classified human GBM samples as well as brains from mice transplanted with GBM CSCs/GCLs. Primary antibodies used for the stainings were: goat anti-PECAM-1 (CD31) (M-20) (Santacruz Biotechnology), rabbit anti-Iba1 (Wako Chemical GmbH), goat anti-PDGFR (RD Systems) and goat anti-SPARCL1 (RD Systems).
Sections were then incubated with the secondary antibody (ChemMATE Envision Rabbit/Mouse, Dako Cytomation). Vessel number and area were quantified by the software ImageJ Lysates from CSCs and GCLs were homogenized in 10x volume of RIPA lysis buffer. Proteins were separated by electrophoresis on 8-10% polyacrilamide (Sigma-Aldrich, St. Louis, MO) gels and transferred onto trans-blot nitrocellulose membranes (Amersham). The primary antibodies/antisera used were goat anti-SPARCL1 (RD Systems), rabbit anti-ADAMTS4 (Novus Biological) and mouse anti-calnexin (Genetex). Secondary antibodies were horseradish peroxidase-conjugated (Amersham).
Reactive proteins were visualized using LiteBlot (Euroclone, Padriciano, Italy) and exposure to x-ray film (BioMax MR; Kodak, Rochester, NY).
Generation of lentiviral vectors for gene expression
The cDNA for human SPARCL1 (Upstate, Lake Placid, NY, USA) was cloned into the pC.sin.cPPT.PGK.GFP.WPRE11 monocistronic transfer lentiviral vector (LV) in place of the GFP sequence. The pCCL.sin.cPPT.PGK.GFP.WPRE11 vector was used as mock condition. GBM CSCs and GCLs were transduced with 1x10 7 TU/ml of LVs for 16 hours.
Orthotopic implantation of GBM cells
All animal experiments were approved by the Institutional Ethics Review Board at San Raffaele Scientific Institute and by the Italian Ministry of Health and performed in accordance with the guidelines of the International Animal Care and Use Committee.
Two x10 5 CSCs/GCLs were suspended in 2µl of DMEM supplemented with DNase and delivered into the right striatum of 8-week old nu/nu female mice by stereotactic injection with a micro-syringe (Hamilton). For MRI studies, 1x10 6 GBM CSCs were suspended in 5µl of DMEM and injected into the right striatum of 4-week old Rowett Nude female rats.
Chorioallantoic membrane (CAM) assay
Alginate beads (5 µL) containing GBM CSCs (3x10 4 cells/embryo) were placed on top of the chicken embryo CAM of fertilized White Leghorn chicken eggs at day 11 of incubation (6 to 8 eggs per experimental group) (Ribatti et al., 1997) . After 72 hours, blood vessels converging toward the implant were counted under a stereomicroscope (STEMI-SR, x2/0.12; Zeiss) at 20X magnification. 
MRI acquisition and analysis
Microglia depletion by CSFR1 pharmacological inhibition
For treatment with GW2580, mice were fed with 0.1% GW2580 (Selleckchem) assembled to chow (D17121401i, Research Diets) or vehicle in control chow (D1001i, Research Diets) (Olmos-Alonso et al., 2016) , whereas for treatment with PLX 3397, they were fed with pexidartinib (Selleckchem) assembled to chow (290mg/kg, D15082602i, Research Diets) or the same control chow as above.
Mice to be transplanted with the different U87 GCL populations started being fed with control or GW2580-containing chow 10 days before transplantation and with PLX3397-containing chow 7 days before transplantation. Treatment continued for 14 days after transplantation.
Three x10 5 U87 GCLs were suspended in 3µl of DMEM supplemented with DNase and delivered into the right striatum of 8-week old NSG female mice by stereotactic injection with a micro-syringe (Hamilton). Tumor development was monitored by T2-weighted MRI and mice were sacrificed 2 weeks after transplant.
Statistics
For experiments involving patients' samples or in vitro CSC/GCL cultures, n represents the number of single patient-derived samples and CSC lines. For experiments involving transplanted CSC/GCL lines, n represents the number of individual animals that were transplanted with a single cell line.
Results for continuous variables were expressed as mean ± standard error mean (s.e.m.). Two-group comparisons were performed with the independent samples' one-tailed Student t test. P values <0.05 were considered statistically significant. *:p<0.05; **: p<0.01; ***: p<0.005; ****: p<0.001. (C) SPARCL1 expression is higher in EGFR neg than in EGFR pos CSC-derived tumors (IHC) (SPARCL1, brown) (n=3 for each type). Scale bar: 50µm.
(D) SPARCL1 is highly expressed in human PN, neural, classical and MES GBM subgroups as reported in dataset Tumor Glioblastoma-TCGA-540-MAS5.0.
(E) SPARCL1 protein expression by IHC is retrieved with a similar pattern in GBM specimens classified as PN and MES (n=6 and n=10 patients for PN and MES, respectively). Scale bar: 50µm. (E) SPARCL1-overexpressing CSCs exert a significant pro-angiogenic effect when seeded in direct contact with the membrane in the CAM assay than the CM from the same cells. Increased vessel density is indicated by arrows. (E) Pearson correlation analysis between SPARCL1 expression and immune infiltrate markers. Ibal1
and CD11b are total TAM-associated markers; CD163 and iNOS are M2-associated markers. (D) Tumor volume as measured by T2-weighted imaging (yellow line) is smaller than the tumor volume segmented on isotropic diffusion maps (blue line). 
